NZ631126A - Contaminant removal method - Google Patents

Contaminant removal method

Info

Publication number
NZ631126A
NZ631126A NZ631126A NZ63112614A NZ631126A NZ 631126 A NZ631126 A NZ 631126A NZ 631126 A NZ631126 A NZ 631126A NZ 63112614 A NZ63112614 A NZ 63112614A NZ 631126 A NZ631126 A NZ 631126A
Authority
NZ
New Zealand
Prior art keywords
apo
log
solution
lrv
enveloped virus
Prior art date
Application number
NZ631126A
Other languages
English (en)
Inventor
Vucica Yvonne
Lee Warren Gary
Kempf Christoph
Stucki Martin
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of NZ631126A publication Critical patent/NZ631126A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ631126A 2013-08-08 2014-08-08 Contaminant removal method NZ631126A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13179755 2013-08-08
PCT/AU2014/000790 WO2015017888A1 (en) 2013-08-08 2014-08-08 Contaminant removal method

Publications (1)

Publication Number Publication Date
NZ631126A true NZ631126A (en) 2018-06-29

Family

ID=48948309

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ631126A NZ631126A (en) 2013-08-08 2014-08-08 Contaminant removal method

Country Status (13)

Country Link
US (3) US10087235B2 (https=)
EP (2) EP3418290A1 (https=)
JP (1) JP6530394B2 (https=)
KR (1) KR102437202B1 (https=)
CN (2) CN105452291B (https=)
AU (1) AU2014305646C1 (https=)
CA (1) CA2920391C (https=)
DK (1) DK3030578T3 (https=)
ES (1) ES2689333T3 (https=)
HK (1) HK1225737B (https=)
NZ (1) NZ631126A (https=)
PL (1) PL3030578T3 (https=)
WO (1) WO2015017888A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3418290A1 (en) * 2013-08-08 2018-12-26 CSL Ltd. Contaminant removal method
JP2021513913A (ja) * 2018-02-19 2021-06-03 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 修正フィルタ膜及び方法
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
CN113766952B (zh) * 2019-03-29 2023-09-08 国立研究开发法人量子科学技术研究开发机构 放射性药品的制造方法及放射性药品
CN111351893A (zh) * 2020-04-28 2020-06-30 黄河三角洲京博化工研究院有限公司 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
CA2489123C (en) 2002-06-14 2011-03-15 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
EP2522674A1 (en) 2007-08-17 2012-11-14 CSL Behring GmbH Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
WO2009036460A2 (en) 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
MX2012014928A (es) * 2010-06-30 2013-03-22 Csl Ltd Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.
EP2673296B1 (en) * 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
EP3004160B1 (en) 2013-06-05 2022-12-28 CSL Limited Process for preparing apolipoprotein a-i (apo a-i)
EP3418290A1 (en) * 2013-08-08 2018-12-26 CSL Ltd. Contaminant removal method
CN104017076B (zh) * 2014-01-06 2016-07-06 宁波博泰生物技术有限公司 载脂蛋白aⅰ抗血清的制备方法

Also Published As

Publication number Publication date
AU2014305646C1 (en) 2019-01-17
AU2014305646A1 (en) 2016-02-18
KR102437202B1 (ko) 2022-08-29
US11732028B2 (en) 2023-08-22
PL3030578T3 (pl) 2018-12-31
US20160176947A1 (en) 2016-06-23
KR20160040299A (ko) 2016-04-12
CA2920391A1 (en) 2015-02-12
CN109701004B (zh) 2022-11-08
US10730927B2 (en) 2020-08-04
CA2920391C (en) 2023-03-28
US20190119354A1 (en) 2019-04-25
EP3030578A4 (en) 2017-04-26
EP3030578B1 (en) 2018-07-04
WO2015017888A1 (en) 2015-02-12
AU2014305646B2 (en) 2018-06-14
EP3030578A1 (en) 2016-06-15
CN105452291A (zh) 2016-03-30
HK1225737B (en) 2017-09-15
CN109701004A (zh) 2019-05-03
DK3030578T3 (en) 2018-10-15
ES2689333T3 (es) 2018-11-13
WO2015017888A8 (en) 2015-10-01
JP6530394B2 (ja) 2019-06-12
US10087235B2 (en) 2018-10-02
US20210147509A1 (en) 2021-05-20
CN105452291B (zh) 2019-03-19
EP3418290A1 (en) 2018-12-26
JP2016528233A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
NZ631126A (en) Contaminant removal method
MX386767B (es) Filtración de virus de medio de cultivo celular.
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
WO2008036899A3 (en) Methods for removing viral contaminants during protein purification
Werner et al. Particle contamination of parenteralia and in-line filtration of proteinaceous drugs
RU2013147609A (ru) Новые способы очистки белка
MY194294A (en) Novel viral replication inhibitors
IN2014DN03291A (https=)
EA201690541A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
MX374287B (es) Formulacion que contiene virus y uso de la misma.
IN2014DN09173A (https=)
MX378091B (es) Composicion neuroprotectora anticolinergica y metodos.
AR061894A1 (es) Vacunas para malaria
ATE412402T1 (de) Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
JP2016528233A5 (https=)
RU2015155602A (ru) Способ получения аполипопротеина a-i (аро a-i)
EP4198043A1 (en) Method for producing an antigen corresponding to the inactivated sars-cov-2 virus, antigen corresponding to the inactivated sars-cov-2 virus, antigenic composition, kits, and uses thereof
JP5112060B2 (ja) ウイルス安全性生物学的流体の調製のための方法
MA35303B1 (fr) Vaccin contre la rhinite equine
US20140314871A1 (en) Method for purifying bee venom on mass scale
BR112016007669A2 (pt) ácido {4-[5-(3-cloro fenóxi) oxazol [5,4-d] pirimidin-2-il]-2,6-dimetil fenóxi} acético para uso na prevenção ou tratamento de dano agudo dos rins
EP4119134C0 (fr) Composition pharmaceutique destinée à inhiber l'infectiosité des virus à bicouche lipidique, à traiter les maladies associées et leurs complications
BR102021015972B1 (pt) Processo de produção de um antígeno, correspondente aos vírus sars-cov-2 inativado, antígeno, correspondente aos vírus sars-cov-2, inativado, composição antigênica, kits e seus usos
JP2013001686A5 (https=)
Conhaim et al. Tissue Plasminogen Activator (TPA) Reduces Lung Injury After Acute Blood Loss In Rats

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 AUG 2021 BY SPRUSON + FERGUSON

Effective date: 20181109

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2022 BY CPA GLOBAL

Effective date: 20210624

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2023 BY CPA GLOBAL

Effective date: 20220623

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2024 BY CPA GLOBAL

Effective date: 20230622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240627

LAPS Patent lapsed